血清sCD163水平与糖尿病性骨质疏松的关系

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (613 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the correlation of the bone mineral density (BMD) in patients with type 2 diabetes mellitus with sCD163. Methods From January 2015 to April 2016, in 425th Hospital of PLA, 82 patients with type 2 diabetes mellitus were selected as DM group, DM group was divided into osteoporotic DM group (45 cases) and non-osteoporotic DM group (37 cases), at the same time, 30 healthy persons were enrolled as the control group. BMD of lumbar span (L1-L4) was measured with dual energy X-ray absorptiometry, the levels of FPB and HbA1c were analysed by automatic biochemistry analyzer. The serum level of sCD163 was detected by ELISA. Results The levels of FGP, HbA1c, sCD163 in DM group were significantly higher than those in control group (P < 0.05). The BMD in DM group was significantly lower than that in control group (P < 0.05). The level of sCD163 in osteoporotic DM group was significantly higher than that in non-osteoporotic DM group (P < 0.05), and the level of BMD more declined in osteoporotic DM group than that in non-osteoporotic DM group (P < 0.05). Furthermore, the result of Pearson correlation analysis indicated that BMD was negatively correlated with sCD163 (r = -0.880, P < 0.05). Logistic regression analysis indicated that in DM patients sCD163 was the risk factor for osteoporosis (OR = 1.490, P < 0.05). Conclusion The increased level of sCD163 is related to the osteoporosis in DM.

Key words： Diabetes mellitus Osteoporosis Bone mineral density sCD163

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Aibao1 ZENG Guoqing1 GONG Qi2 YANG Xuehong1 MU Jihong1

Cite this article:

CHEN Aibao1 ZENG Guoqing1 GONG Qi2 YANG Xuehong1 MU Jihong1. Relationship of bone density with sCD163 in diabetic osteoporosis[J]. 中国医药导报, 2017, 14(27): 101-104.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I27/101

[1] Blakytny R，Spraul M，Jude EB. Review：the diabetic bone： a cellular and molecular perspective [J]. Int J Low Extrem Wounds，2011，10（1）：16-32.
[2] Jung JK，Kim HJ，Lee HK，et al. Fracture incidence and risk of osteoporosis in female type 2 diabetic patients in Korea [J]. Diabetes Metab J，2012，36（2）：144-150.
[3] Redlich K，Smolen JS. Inflammatory bone loss： pathogenesis and therapeutic intervention [J]. Nat Rev Drug Discov，2012，11（3）：234-250.
[4] Wang TT，He CQ，Yu XJ. Pro-inflammation cytokines： new potential therapeutic targets for obesity-related bone disorders [J]. Curr Drug Targets，2017. [Epub ahead of print].
[5] Colafrancesco S，Priori R，Alessandri C，et al. The hyperferritinemic syndromes and CD163：a marker of macrophage activation [J]. Isr Med Assoc J，2014，16（10）：662-663.
[6] Deichgr?覸ber P，Witte DR，M?覬ller HJ，et al. Soluble CD163，adiponectin，C-reactive protein and progression of dysglycaemia in individuals at high risk of type 2 diabetes mellitus：the ADDITION-PRO cohort [J]. Diabetologia，2016，59（11）：2467-2476.
[7] Samuelsson M，Dereke J，Svensson MK，et al. Soluble plasma proteins ST2 and CD163 as early biomarkers of nephropathy in Swedish patients with diabetes，15-34 years of age：a prospective cohort study [J]. Diabetol Metab Syndr，2017，9：41.
[8] Kobayashi Y，Yoshida S，Nakama T，et al. Overexpression of CD163 in vitreous and fibrovascular membranes of patients with proliferative diabetic retinopathy：possible involvement of periostin [J]. Br J Ophthalmol，2015，99（4）：451-456.
[9] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2010年版）[J].中国糖尿病杂志，2012，20（1）：S1-S37.
[10] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南（2011）[J].中国骨质疏松和骨矿盐疾病杂志，2011，4（1）：2-17.
[11] Dede AD，Tournis S，Dontas I，et al. Type 2 diabetes mellitus and fracture risk [J]. Metabolism，2014，63（12）：1480-1490.
[12] Wongdee K，Krishnamra N，Charoenphandhu N. Derangement of ca1cium metabolism in diabetes mellitus：negative outcome from the synergy between impaired bone turnover and intestinal ca1cium absorption [J]. J Physiol Sci，2017，67（1）：71-81.
[13] Sapa A，Rak A，Wybieralska M，et al. Diagnostic usefulness of sCD163，proca1citonin and neopterin for sepsis risk assessment in critically ill patients [J]. Adv Clin Exp Med，2017，26（1）：101-108.
[14] Parkner T，S?覬rensen LP，Nielsen AR，et al. Soluble CD163：a biomarker linking macrophages and insulin resistance [J]. Diabetologia，2012，55（6）：1856-1862.
[15] Cinkajzlová A，Lacinová Z，Klou■ková J，et al. An alternatively activated macrophage marker CD163 in severely obese patients：the influence of very low-calorie diet and bariatric surgery [J]. Physiol Res，2017 Apr 12. [Epub ahead of print]
[16] Kobayashi Y，Yoshida S，Nakama T，et al. Overexpression of CD163 in vitreous and fibrovascular membranes of patients with proliferative diabetic retinopathy：possible involvement of periostin [J]. Br J Ophthalmol，2015，99（4）：451-456.
[17] 王祥德，郑红波. 糖尿病动脉粥样硬化患者血清sCD163和oxLDL 检测的临床意义[J].现代实用医学，2013，25（5）：520-521.
[18] Ruscitti P，Cipriani P，Carubbi F，et al. The role of IL-1β in the bone loss during rheumatic diseases [J]. Mediators Inflamm，2015，2015：782382.
[19] Roy B，Curtis ME，Fears LS，et al. Molecular mechanisms of obesity-induced osteoporosis and muscle atrophy [J]. Front Physiol，2016，29（7）：439. eCollection 2016.
[20] Liu Y，Almeida M，Weinstein RS，et al. Skeletal inflammation and attenuation of Wnt signaling，Wnt ligand expression，and bone formation in atherosclerotic ApoE-null mice [J]. Am J Physiol Endocrinol Metab，2016，310（9）：E762-E773.